Teva Pharmaceutical Industries Limited
TEVA
$16.33
-$0.13-0.79%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.40% | 9.81% | 8.47% | 7.22% | 6.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.40% | 9.81% | 8.47% | 7.22% | 6.16% |
| Cost of Revenue | 3.40% | 1.68% | 0.34% | 0.74% | 3.13% |
| Gross Profit | 5.48% | 19.43% | 18.25% | 14.94% | 9.62% |
| SG&A Expenses | 5.80% | 6.35% | 4.69% | 3.93% | 1.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -175.00% | -101.64% | -83.58% | -112.12% | -80.65% |
| Total Operating Expenses | 3.99% | 2.64% | 2.11% | 1.59% | 2.98% |
| Operating Income | 6.07% | 45.27% | 40.63% | 35.74% | 21.04% |
| Income Before Tax | -106.43% | 77.27% | 93.58% | 66.65% | 80.19% |
| Income Tax Expenses | 11,350.00% | 574.51% | 174.66% | 94.12% | 99.07% |
| Earnings from Continuing Operations | -218.02% | 49.90% | 69.35% | 56.53% | 75.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 471.43% | 180.43% | 206.19% | 240.45% | 5.66% |
| Net Income | -192.68% | 58.96% | 80.72% | 71.99% | 77.10% |
| EBIT | 6.07% | 45.27% | 40.63% | 35.74% | 21.04% |
| EBITDA | 2.28% | 27.27% | 23.09% | 18.98% | 10.11% |
| EPS Basic | -188.79% | 59.79% | 81.22% | 72.20% | 77.25% |
| Normalized Basic EPS | 29.93% | 86.62% | 81.07% | 67.79% | 23.90% |
| EPS Diluted | -181.76% | 59.09% | 80.58% | 71.46% | 76.58% |
| Normalized Diluted EPS | 31.09% | 86.42% | 80.19% | 66.91% | 23.01% |
| Average Basic Shares Outstanding | 1.01% | 0.96% | 0.92% | 0.85% | 0.86% |
| Average Diluted Shares Outstanding | 0.33% | 1.00% | 1.41% | 1.35% | 1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
